- Home
- FSEA vs IMA Comparison
FSEA vs IMA Comparison
Compare FSEA & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSEA | IMA |
|---|---|---|
| Founded | 1890 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 66.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FSEA | IMA |
|---|---|---|
| Price | $17.17 | $5.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 3.0K | ★ 10.0K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.08 | $3.94 |
| 52 Week High | $17.21 | $9.20 |
Technical Indicators
Market Signals| Indicator | FSEA | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 70.87 | 38.71 |
| Support Level | $16.84 | $3.94 |
| Resistance Level | $17.21 | $6.13 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 93.75 | 21.02 |
Price Performance
Historical ComparisonAbout FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.